

Зміст

Ювілеї

- До 90-річного ювілею
Кожем'яка Анатолій Іванович 5

Клінічна педіатрія

- Мозирська О.В.*
Роль топічної антимікотичної терапії
в лікуванні atopічного дерматиту в дітей 7
- Тимошина О.В., Овчаренко Л.С.,
Вертегел А.О., Андрієнко Т.Г.,
Самохін І.В., Кряжев О.В.*
Вікові особливості поглинальної
та цитокініндукуючої функції фагоцитозу
у дітей, які часто хворіють на гострі
респіраторні інфекції 12
- Товарницька А.О.*
Вплив грудного вигодовування на закриття
відкритої артеріальної протоки
в недоношених новонароджених 18
- Снісарь В.І., Миронов Д.В.*
Особливості реакцій організму дітей
з онкологічними захворюваннями
при внутрішньовенній анестезії
з пропофолом 26

Випадок із практики

- Никитюк С.О., Левенець С.С., Борис З.Я.*
Токсикодермія в дитини
як ускладнення після укусів клопів 33

Огляд літератури

- Леженко Г.О., Абатуров О.Є., Погрібна А.О.*
Клінічне значення фероптозу
як заліозалежної регульованої загибелі
клітин у загальній структурі захворювання 38

Теоретична медицина

- Абатуров О.Є., Бабич В.Л.*
Механізми дії цитоплазматичних мікроРНК.
Частина 3. TNRC6-асоційований
механізм мікроРНК-опосередкованої
деградації мРНК 43

Contents

Jubilees

- To the 90th anniversary
of Kozhemiaka Anatolii Ivanovych 5

Clinical Pediatrics

- O.V. Mozyrska*
Role of antifungal therapy in the treatment
of atopic dermatitis in children 7
- O.V. Tymoshyna, L.S. Ovcharenko,
A.O. Vertehel, T.G. Andrienko,
I.V. Samokhin, O.V. Kryazhev*
Age-specific features of the absorptive
and cytokine-inducing function of phagocytosis
in children with recurrent acute respiratory
infections 12
- A.O. Tovarnytska*
Breastfeeding impact
on patent ductus arteriosus closure
in preterm newborns 18
- V.I. Snisar, D.V. Myronov*
Features of body reactions
in children with oncological
diseases during intravenous
anesthesia with propofol 26

Case Report

- S.O. Nykytyuk, S.S. Levenets, Z.Ya. Borys*
Toxicoderma in a child as
a complication after a bedbug bite 33

Review of Literature

- H.O. Lezhenko, A.E. Abaturon, A.O. Pogribna*
Clinical significance of ferroptosis
as iron-dependent regulated cell death
in the general structure of the disease 38

Theoretical Medicine

- A.E. Abaturon, V.L. Babych*
Mechanisms of action of cytoplasmic microRNAs.
Part 3. TNRC6-associated mechanism
of miRNA-mediated mRNA
degradation 43

H.O. Lezhenko¹, A.E. Abaturov², A.O. Pogribna¹¹Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine²Dnipro State Medical University, Dnipro, Ukraine

Clinical significance of ferroptosis as iron-dependent regulated cell death in the general structure of the disease

Abstract. *In this article, we have analysed the studies that determined the iron-dependent regulated type of cell death, ferroptosis, described the fundamental morphological and biochemical differences between various types of regulated cell death, highlighted modern scientific achievements in understanding the features of the above-mentioned process, described the clinical significance of ferroptosis in the general structure of morbidity and identified relevant issues for further research. Conclusions.* Numerous studies allowed identifying ferroptosis as a form of regulated cell death, initiated by oxidative disturbances of the intracellular microenvironment, which is under the constitutive control of glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants. Ferroptosis can occur in two main ways: external (transport) and internal (enzymatic). The external pathway is based on non-enzymatic reactions, such as the iron-dependent Fenton reaction. The internal pathway is mediated by enzyme systems, including glutathione peroxidase 4 and lipoxygenase. Conducting clinical research will improve not only the understanding of the role of ferroptosis in the pathogenesis of the course of diseases, but also reveal possible preventive strategies for the development of pathological processes.

Keywords: *ferroptosis; cell death; review*

An excess of free reactive iron can cause various types of cell death, including the recently recognized type — ferroptosis. The field of ferroptosis research has grown exponentially over the past few years since the term was coined in 2012.

The definition of ferroptosis as a separate form of cell death was preceded by studies from 1955 [1] the stages of which can be conventionally distinguished as:

I. The role of lipid peroxidation in cell death (1962–2005).

II. The significance of cysteine deprivation for cell death (1955–2005).

III. The role of glutathione peroxidase 4 in cell death (1982–2003).

IV. Importance of polyunsaturated fatty acid peroxidation for cell death (2006–2008).

Although the main molecular effector of the process remains poorly understood, it is known that ferroptosis is induced by the activation of iron-dependent lipid peroxi-

dation [2]. Significant progress has been made in analyzing the mechanisms that lead to lipid peroxidation and how antioxidant systems or stress proteins regulate ferroptosis. Ferroptosis is a special variant of cell death in view of its important role in the initiation and development of diseases, including inflammatory diseases, and the determination of its inhibitors allows evaluating the preventive effect on experimental models of certain pathological processes, such as cancer. However, some studies suggest that ferroptosis may be a physiological process that occurs widely in the body of mammals, rather than a pathological or organ-specific one [3].

However, the scientific community today defines ferroptosis as an iron-dependent programmed cell death pathway, mainly due to redox imbalance, which has categorically different biological and morphological characteristics compared to other cell death patterns [4].

Given the fact that apoptosis was the first discovered and studied mechanism of regulated cell death, necrosis and py-

roptosis were recently distinguished alongside it [5]. However, ferroptosis categorically differs from apoptosis, necrosis and pyroptosis in terms of morphological and physiological characteristics [5–14]. Currently, ferroptosis is classified by a number of mechanisms (necroptosis, pyroptosis, NETosis, parthanatos), defined as “regulated necrosis” [15, 16]. Unlike apoptosis, which is characterized by cytoplasm shrinkage, nuclear division, chromatin condensation, chromosomal DNA division [8, 14] and the release of mitochondrial cytochrome C [15], and necrosis, which is characterized by cytoplasmic granulation, swelling of organelles and cells, loss of cell membrane integrity and, ultimately, leakage of cellular contents [16], during ferroptosis, cell nuclei remain intact, chromatin does not aggregate [17, 18], the plasma membrane does not rupture, and contracting mitochondria exhibit a greater inner membrane density while the outer membrane ruptures. Ultrastructural analysis also showed that the mitochondria of ferroptotic cells lose structural integrity and have a different morphological structure (smaller size) [19], whereas mitochondria in apoptotic cells are usually “bloated” [20]. Unlike apoptosis, ferroptosis exhibits immunogenicity [21], as affected cells release damage-associated molecular patterns and alarmins, which enhance cell death and promote a number of reactions associated with inflammation [15, 22–24].

It was determined that the precursor to the understanding of the process of ferroptosis was oxytosis, which had several characteristics in common with the latter, such as: the role of lipoxygenase, the production of reactive oxygen species, and gene expression [25]. However, the discovery of the compound erastin, which was able to initiate ferroptotic cell death, played a significant role in identifying the mechanism of ferroptosis [19]. Stockwell et al. (2017) research [26] allowed identifying ferroptosis as a form of regulated cell death, initiated by oxidative disturbances of the intracellular microenvironment, which is under the constitutive control of glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants [14]. Glutathione peroxidase 4 is one of the central regulators of ferroptosis [27]. Glutathione acts as a cofactor of glutathione peroxidase 4 and maintains its level by exchanging glutamate and cystine through the x_c^- antiporter system [26, 27]. Studies of ferroptosis have shown the crucial role of mitochondria in its occurrence through lipid metabolism, energy metabolism, iron metabolism and other regulatory processes in mitochondria [28]. The decreased reduction of lipid peroxides caused by the inhibition of glutathione peroxidase 4, and increased formation of lipid peroxides from arachidonoyl are the two main pathways that lead to ferroptosis [3]. Further studies showed that ferroptosis is mediated by mitochondrial voltage-dependent anion channels (VDACs), and erastin-induced opening of VDAC2/3 leads to mitochondrial iron uptake, reactive oxygen species formation, increased mitochondrial potential, and oxidative stress-induced ferroptosis [6, 29]. Since this discovery, the complex interplay between iron, cysteine and lipid metabolism has emerged as an important regulator of ferroptosis [30], and a number of its regulators have been identified. Other organelles besides mitochondria are also involved in ferroptosis. Oxidative stress associated with the endoplasmic reticulum, Golgi

stress-related lipid peroxidation, and lysosomal dysfunction contribute to the induction of ferroptosis [31].

The most important biochemical features of ferroptosis are increased levels of lipid hydroperoxides and concentrations of ferrous ions (Fe^{2+}), as ferroptotic cells produce an excessive amount of reactive oxygen species, which initiates lipid peroxidation through the Fenton reaction, and an enzymatic mechanism with the participation of lipoxygenase [21]. The Fenton reaction partially explains the dependency of ferroptosis on iron, as redox pools of iron can directly catalyze the spread of lipid peroxidation with the synthesis of pathological compounds that will induce the release of cellular iron [1].

The genetic control system of ferroptosis is excellent compared to other types of cell death. Six genes encoding putative mitochondrial proteins, ribosomal protein L8 (RPL8), iron-responsive element-binding protein 2 (IREB2), ATP synthase, citrate synthase (CS) proteins, tetratricopeptide repeat domain 35 (TTC35) and acyl-CoA synthetase family member 2 (ACSF2) were isolated. In addition, TFRC, ISCU, FTH1, and FTL are key ferroptosis genes that control erastin sensitivity, iron uptake, metabolism, and storage by influencing Fe^{2+} levels [24]. Dixon et al. (2012) identified the specific role of RPL8, IREB2, ATP5G3, TTC35, CS, and ACSF2 in erastin-induced ferroptosis [19].

Translational and transcriptional regulation of iron homeostasis provide an integrated network for determining ferroptosis sensitivity [32]. The iron-dependent mechanism of ferroptosis creates conditions for peroxidation of phospholipid membranes rich in polyunsaturated fatty acids, which leads to cell death. Understanding the mechanism of lipid peroxidation emphasizes the important role of iron and reactive oxygen species in ferroptosis. After all, iron is a redox metal that participates in the formation of free radicals and the spread of lipid peroxidation, and therefore, an increase in its level can increase the vulnerability to ferroptosis [33]. Inhibition of SLC7A11 and glutathione peroxidase 4 leads to accumulation of iron-dependent lipid peroxidation, thus causing the death of ferroptotic cells. The specific iron-dependent mechanisms of ferroptosis remain poorly understood, but currently we can determine the unconditional role of the following components of iron metabolism:

- iron chelators block the death of ferroptotic cells *in vitro* and *in vivo* [19];
- an increase in cellular labile iron is usually observed during the induction of ferroptosis [34];
- exogenic iron supplementation increases the sensitivity of cells to inducers of ferroptosis (for example, erastin) [19];
- an excess of heme and non-heme iron can directly induce ferroptosis [35];
- several heme and non-heme iron-containing enzymes, such as ALOX, NOX and CYP, are responsible for the process of lipid peroxidation [18, 19, 36–38];
- iron-mediated production of reactive oxygen species via the Fenton reaction contributes to lipid peroxidation in ferroptosis [24].

The transporter protein transferrin is necessary for the induction of ferroptotic cell death. For example, cell death

caused by amino acid deficiency takes the form of ferroptosis instead of apoptosis or necroptosis. This amino acid starvation-induced ferroptosis is likely a consequence of cystine starvation and subsequent cellular depletion of GSH. A substance without macromolecules (for example, transferrin) is unable to mimic ferroptosis-inducing activity, while the addition of recombinant iron-saturated holotransferrin induces cell death under the same conditions [39]. These findings indicate that transferrin is a key positive regulator of the ferroptosis process [32].

Importantly, all aspects of iron metabolism, including iron uptake, storage, export, and utilization, have important regulatory effects on ferroptosis [2].

A common feature of ferroptosis is the iron-dependent accumulation of lipid reactive oxygen species and subsequent depletion of phospholipids and polyunsaturated fatty acids [40]. Chains of polyunsaturated fatty acids of membrane lipids are more susceptible to both enzymatic and non-enzymatic oxidation, which leads to their fragmentation [41]. In turn, reactive oxygen species include singlet oxygen molecules and three types of free radicals: hydroxyl radicals, superoxide anions and hydrogen peroxide. Reactive oxygen species regulate several cellular functions at optimal concentrations and homeostatic balance. However, at critically high concentrations, reactive oxygen species can cause DNA damage, protein denaturation, and induce lipid peroxidation [42]. In this process, catalyzed by iron and oxygen, membrane destruction and cell death occur [21].

Today, ferroptosis is defined as a pathogenetic factor of damage to the tissues of the brain, heart, liver, and renal tubules, blood flow stoppage, sleep apnea, which developed against the background of tissue ischemia/reperfusion [42]. Ferroptosis disrupts the normal immune response by killing T-lymphocytes, which has been proven in mice. The ferroptotic process is a companion of neurodegenerative diseases, which is not surprising, since nerve cells are distinguished by the maximum content of polyunsaturated fatty acids, and some pathologies of the nervous system, including Alzheimer's, Parkinson's and Huntington's diseases, are due to the inability to restore oxidized lipids. Some clinical studies demonstrated an increased iron level in the brain of children with severe ischemic-anoxic stroke [43]. In addition, it was found that elevated level of iron against the background of ischemia/perfusion is a mediator of tissue damage. In support of this scientific claim, reduction of brain damage in response to iron chelation has been demonstrated in several animal models [44].

Interestingly, recent studies have shown that ferroptosis is also involved in the development of inflammatory bacterial diseases. Anthony Muthu T. et al. (2021) found that *Pseudomonas aeruginosa* can cause ferroptosis in human bronchial epithelial cells by generating lipoxygenase [45]. Observations are described on the role of *Mycobacterium tuberculosis* in ferroptotic cell damage by inhibiting glutathione peroxidase 4 [46]. Unlike immunologically silent cells that undergo apoptosis, ferroptotic targets are inherently more immunogenic because they release inflammatory cytokines and damage-associated molecular patterns, skewing the environment to a pro-inflammatory state [22].

Our study made it possible to analyze the likely role of ferroptosis in the development of anemia of inflammation in young children with acute inflammatory bacterial diseases of the respiratory organs [47, 48].

However, we believe that it is wrong to perceive ferroptosis exclusively as a pathological process. It is appropriate to recall that ferroptosis was determined directly during research aimed at the treatment of oncological diseases [19]. Modern data on its ability to inhibit the growth of tumors allow expanding the understanding of the role of ferroptosis in the body.

Therefore, the study of ferroptosis allows establishing a new scientific platform, which can be aimed at studying the clinical significance of ferroptosis in the development of a number of pathological processes, determining new preventive and treatment strategies for diseases, and answering the following questions:

— The effect of ferroptosis on the inflammatory reaction is not absolute; under what circumstances will the induction of ferroptosis have a pro-inflammatory or anti-inflammatory effect?

— Is it possible to determine the ways to regulate ferroptosis, which will allow improving treatment tactics?

— Since ferroptosis is closely related to inflammation and oncological process, does it play a role in inflammation-mediated carcinogenesis?

Conclusions

1. Numerous studies allowed identifying ferroptosis as a form of regulated cell death, initiated by oxidative disturbances of the intracellular microenvironment, which is under the constitutive control of glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants.

2. Ferroptosis can occur in two main ways: external (transport) and internal (enzymatic). The external pathway is based on non-enzymatic reactions, such as the iron-dependent Fenton reaction. The internal pathway is mediated by enzyme systems, including glutathione peroxidase 4 and lipoxygenase.

3. Conducting clinical research will improve not only the understanding of the role of ferroptosis in the pathogenesis of the course of diseases, but also reveal possible preventive strategies for the development of pathological processes.

References

1. Hirschhorn T., Stockwell B. *The development of the concept of ferroptosis. Free Radical Biology and Medicine.* 2019. 133. 130-143. doi: 10.1016/j.freeradbiomed.2018.09.043.
2. Kuang F., Liu J., Tang D., Kang R. *Oxidative damage and antioxidant defense in ferroptosis. Frontiers in Cell and Developmental Biology.* 2020. 8. doi: 10.3389/fcell.2020.586578.
3. Lei P., Bai T., Sun Y. *Mechanisms of ferroptosis and relations with regulated cell death: a review. Frontiers in Physiology.* 2019. 10. doi: 10.3389/fphys.2019.00139.
4. Han C., Liu Y., Dai R., Ismail N., Su W., Li B. *Ferroptosis and its potential role in human diseases. Frontiers in Pharmacology.* 2020. 11. doi: 10.3389/fphar.2020.00239.
5. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E., Baehrecke E. et al. *Classification of cell death: recommendations of the No-*

- menclature Committee on Cell Death 2009. *Cell Death & Differentiation*. 2008. 16(1). 3-11. doi: 10.1038/cdd.2008.150.
6. Yagoda N., von Rechenberg M., Zaganjor E., Bauer A., Yang W., Fridman D. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature*. 2007. 447(7146). 865-869. doi: 10.1038/nature05859.
 7. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. *Nature Reviews Molecular Cell Biology*. 2010. 11(10). 700-714. doi: 10.1038/nrm2970.
 8. Galluzzi L., Vitale I., Abrams J., Alnemri E., Baehrecke E., Blagosklonny M. et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death & Differentiation*. 2011. 19(1). 107-120. doi: 10.1038/cdd.2011.96.
 9. Aachoui Y., Leaf I., Hagar J., Fontana M., Campos C., Zak D. et al. Caspase-11 protects against bacteria that escape the vacuole. *Science*. 2013. 339(6122). 975-978. doi: 10.1126/science.1230751.
 10. Kayagaki N., Stowe I., Lee B., O'Rourke K., Anderson K., Warming S. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 2015. 526(7575). 666-671. doi: 10.1038/nature15541.
 11. Shi J., Zhao Y., Wang K., Shi X., Wang Y., Huang H. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature*. 2015. 526(7575). 660-665. doi: 10.1038/nature15514.
 12. Vande Walle L., Lamkanfi M. Pyroptosis. *Current Biology*. 2016. 26(13). R568-R572. doi: 10.1016/j.cub.2016.02.019.
 13. Wang Y., Gao W., Shi X., Ding J., Liu W., He H. et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature*. 2017. 547(7661). 99-103. doi: 10.1038/nature22393.
 14. Galluzzi L., Vitale I., Aaronson S., Abrams J., Adam D., Agostinis P. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death & Differentiation*. 2018. 25(3). 486-541. doi: 10.1038/s41418-017-0012-4.
 15. Peng J., Song W., Yao F., Zhang X., Peng J., Luo X., Xia X. Involvement of regulated necrosis in blinding diseases: focus on necroptosis and ferroptosis. *Experimental Eye Research*. 2020. 191. 107922. doi: 10.1016/j.exer.2020.107922.
 16. Nirmala J., Lopus M. Cell death mechanisms in eukaryotes. *Cell Biology and Toxicology*. 2019. 36(2). 145-164. doi: 10.1007/s10565-019-09496-2.
 17. Friedmann Angeli J., Schneider M., Proneth B., Tyurina Y., Tyurin V., Hammond V. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nature Cell Biology*. 2014. 16(12). 1180-1191. doi: 10.1038/ncb3064.
 18. Xie Y., Song X., Sun X., Huang J., Zhong M., Lotze M. et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. *Biochemical and Biophysical Research Communications*. 2016. 473(4). 775-780. doi: 10.1016/j.bbrc.2016.03.052.
 19. Dixon S., Lemberg K., Lamprecht M., Skouta R., Zaitsev E., Gleaso C. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*. 2012. 149(5). 1060-1072. doi: 10.1016/j.cell.2012.03.042.
 20. Tang D., Kang R., Berghe T., Vandenabeele P., Kroemer G. The molecular machinery of regulated cell death. *Cell Research*. 2019. 29(5). 347-364. doi: 10.1038/s41422-019-0164-5.
 21. Sun Y., Chen P., Zhai B., Zhang M., Xiang Y., Fang J. et al. The emerging role of ferroptosis in inflammation. *Biomedicine & Pharmacotherapy*. 2020. 127. 110108. doi: 10.1016/j.biopha.2020.110108.
 22. Kim E., Wong S., Martinez J. Programmed necrosis and disease: we interrupt your regular programming to bring you necroinflammation. *Cell Death & Differentiation*. 2018. 26(1). 25-40. doi: 10.1038/s41418-018-0179-3.
 23. Proneth B., Conrad M. Ferroptosis and necroinflammation, a yet poorly explored link. *Cell Death & Differentiation*. 2018. 26(1). 14-24. doi: 10.1038/s41418-018-0173-9.
 24. Martin-Sanchez D., Ruiz-Andres O., Poveda J., Carrasco S., Cannata-Ortiz P., Sanchez-Niño M. et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. *Journal of the American Society of Nephrology*. 2016. 28(1). 218-229. doi: 10.1681/asn.2015121376.
 25. Li Q., Li Q., Jia J., Sun Q., Zhou H., Jin W., Mao X. Baicalein exerts neuroprotective effects in FeCl₃-induced posttraumatic epileptic seizures via suppressing ferroptosis. *Frontiers in Pharmacology*. 2019. 10. doi: 10.3389/fphar.2019.00638.
 26. Stockwell B., Friedmann Angeli J., Bayir H., Bush A., Conrad M., Dixon S. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell*. 2017. 171(2). 273-285. doi: 10.1016/j.cell.2017.09.021.
 27. Yang W., Kim K., Gaschler M., Patel M., Shchepinov M., Stockwell B. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proceedings of the National Academy of Sciences*. 2016. 113(34). doi: 10.1073/pnas.1603244113.
 28. Wang H., Liu C., Zhao Y., Gao G. Mitochondria regulation in ferroptosis. *European Journal of Cell Biology*. 2020. 99(1). 151058. doi: 10.1016/j.ejcb.2019.151058.
 29. Maldonado E., Sheldon K., DeHart D., Patnaik J., Manevich Y., Townsend D. et al. Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells. *Journal of Biological Chemistry*. 2013. 288(17). 11920-11929. doi: 10.1074/jbc.M112.433847.
 30. Friedmann Angeli J., Krysko D., Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. *Nature Reviews Cancer*. 2019. 19(7). 405-414. doi: 10.1038/s41568-019-0149-1.
 31. Wu Y., Zhang S., Gong X., Tam S., Xiao D., Liu S., Tao Y. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. *Molecular Cancer*. 2020. 19(1). doi: 10.1186/s12943-020-01157-x.
 32. Chen X., Yu C., Kang R., Tang D. Iron metabolism in ferroptosis. *Frontiers in Cell and Developmental Biology*. 2020. 8. doi: 10.3389/fcell.2020.590226.
 33. Gao M., Monian P., Pan Q., Zhang W., Xiang J., Jiang X. Ferroptosis is an autophagic cell death process. *Cell Research*. 2016. 26(9). 1021-1032. doi: 10.1038/cr.2016.95.
 34. Hou W., Xie Y., Song X., Sun X., Lotze M., Zeh H. et al. Autophagy promotes ferroptosis by degradation of ferritin. *Autophagy*. 2016. 12(8). 1425-1428. doi: 10.1080/15548627.2016.1187366.
 35. Li Q., Han X., Lan X., Gao Y., Wan J., Durham F. et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. *JCI Insight*. 2017. 2(7). doi: 10.1172/jci.insight.90777.
 36. Yang W., Huang Z., Wu J., Ding C., Murphy S., Chi J. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. *Molecular Cancer Research*. 2020. 18(1). 79-90. doi: 10.1158/1541-7786.mcr-19-0691.
 37. Kagan V., Mao G., Qu F., Angeli J., Doll S., Croix C. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nature Chemical Biology*. 2016. 13(1). 81-90. doi: 10.1038/nchembio.2238.
 38. Zou Y., Li H., Graham E., Deik A., Eaton J., Wang W. et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. *Nature Chemical Biology*. 2020. 16(3). 302-309. doi: 10.1038/s41589-020-0472-6.

39. Gao M., Monian P., Quadri N., Ramasamy R., Jiang X. Glutaminolysis and transferrin regulate ferroptosis. *Molecular Cell*. 2015. 59(2). 298-308. doi: 10.1016/j.molcel.2015.06.011.
40. Yang W., Stockwell B. Ferroptosis: death by lipid peroxidation. *Trends in Cell Biology*. 2016. 26(3). 165-176. doi: 10.1016/j.tcb.2015.10.014.
41. Cheng Z., Li Y. What is responsible for the initiating chemistry of iron-mediated lipid peroxidation: an update. *Chemical Reviews*. 2007. 107(3). 748-766. doi: 10.1021/cr040077w.
42. Kajarabille N., Latunde-Dada G.O. Programmed cell-death by ferroptosis: antioxidants as mitigators. *International Journal of Molecular Sciences*. 2019. 20(19). 4968. doi: 10.3390/ijms20194968.
43. Dietrich R., Bradley W. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. *Radiology*. 1988. 168(1). 203-206. doi: 10.1148/radiology.168.1.3380958.
44. Yan H., Zou T., Tuo Q., Xu S., Li H., Belaidi A., Lei P. Ferroptosis: mechanisms and links with diseases. *Signal Transduction and Targeted Therapy*. 2021. 6(1). doi: 10.1038/s41392-020-00428-9.
45. Anthonymuthu T., Tyurina Y., Sun W., Mikulska-Ruminska K., Shrivastava I., Tyurin V. et al. Resolving the paradox of ferroptotic cell death: ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosis. *Redox Biology*. 2021. 38. 101744. doi: 10.1016/j.redox.2020.101744.
46. Amaral E., Costa D., Namasivayam S., Riteau N., Kamenyeva O., Mittereder L. et al. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. *Journal of Experimental Medicine*. 2019. 216(3). 556-570. doi: 10.1084/jem.20181776.
47. Lezhenko H., Abaturuv O., Pogribna A. Determining the probable role of ferroptosis in the course of inflammatory bacterial diseases of the respiratory organs in young children accompanied by the development of anemia of inflammation. *Pathologia*. 2021. 18(1). 44-49. doi: 10.14739/2310-1237.2021.1.229019.
48. Pogribna A. Prevention of development of anemia of inflammation in young children with acute inflammatory bacterial diseases (Ph. D.). Zaporizhzhia State Medical University. 2022.

Received 03.07.2022

Revised 11.07.2022

Accepted 22.07.2022 ■

Information about authors

Hennadii Lezhenko, MD, Professor, Head of the Department of Hospital Pediatrics, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine; e-mail: genalezh@gmail.com; <https://orcid.org/0000-0003-0851-4586>

Aleksandr Abaturuv, MD, PhD, Professor, Head of the Department of Pediatrics 1 and Medical Genetics, Dnipro State Medical University, Dnipro, Ukraine; <https://orcid.org/0000-0001-6291-5386>
Pogribna A.O., PhD, Assistant at the Department of Hospital Pediatrics, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine; e-mail: a.pogrebnai@gmail.com

Conflicts of interests. Authors declare the absence of any conflicts of interests and own financial interest that might be construed to influence the results or interpretation of the manuscript.

Леженко Г.О.¹, Абатуров О.Є.², Погрібна А.О.¹

¹Запорізький державний медичний університет, м. Запоріжжя, Україна

²Дніпровський державний медичний університет, м. Дніпро, Україна

Клінічне значення фероптозу як залізоалежної регульованої загибелі клітин у загальній структурі захворювання

Резюме. У цій роботі ми проаналізували дослідження, у яких було визначено залізоалежний регульований тип клітинної загибелі — фероптоз, описали принципові морфологічні й біохімічні відмінності різних варіантів регульованої загибелі клітин, висвітлили сучасні наукові досягнення щодо розуміння властивостей перебігу вищевказаного процесу, описали клінічне значення фероптозу в загальній структурі захворюваності та визначили актуальні питання подальших досліджень.

Висновки. Численні дослідження дозволили ідентифікувати фероптоз як форму регульованої клітинної загибелі, ініційовану окислювальними порушеннями внутрішньоклітинного мікрооточення, що знаходиться під конститутивним контролем

глутатіонпероксидази-4 і може бути інгібована хелаторами заліза та ліпофільними антиоксидантами. Фероптоз може бути реалізований двома основними шляхами: зовнішнім (транспортним) та внутрішнім (ферментним). В основі зовнішнього шляху лежать неферментативні реакції, такі як залізоалежна реакція Фентона. Внутрішній шлях відбувається під посередництвом ферментних систем, що включають глутатіонпероксидазу-4 та ліпооксигеназу. Проведення клінічних досліджень дозволить удосконалити не лише розуміння ролі фероптозу в патогенезі перебігу захворювань, але й виявити можливі превентивні стратегії щодо розвитку патологічних процесів.

Ключові слова: фероптоз; клітинна загибель; огляд